engineering
Investment in building and deploying the iX Suite
0.32% to 0.91% of the quarter’s revenue
Incremental total: counts at zero at the point and in full at the high end, with no traced baseline.
our inferencedisclosure: direction only· motive: offensive· before LLMs: expanded
A step from described to directional: the CEO says iX Suite expenditures came down, helped by using AI on the company's own development, while the product grew. No figure. The ledger brackets the spend below the estimated product revenue, , with the point lowered from the prior quarter's share.
Evidence: 3 quotes, 2 confounds, 4 from before coverage
What Concentrix spends to build, deploy and support its AI products: forward-deployed engineers, subject-matter and partner-technology expertise, and the model and compute bill behind iX Hello, which no source splits. It sits across cost of revenue and SG&A.
Why this motive
The spend builds a separately priced product on pace for its recurring revenue level (claim c18) and toward software-like margins at scale (claim c20). Offensive, as the product's.
Before LLMs: expanded
Technology development existed before the iX Suite, and the fiscal 2024 10-K says its cost was historically not material on a stand-alone basis; in fiscal 2024 it rose to approximately of revenue, about a quarter, including iX Suite development and GenAI pilots for clients. That is already the AI-era level, so no pre-AI dollar baseline can be traced. The size is the whole of an activity that existed before.
“Our investment in AI tools remain a key priority, and we're increasing our investment to accelerate deployment of the cutting-edge solutions. While this investment is impacting margins in the short term, we believe that this increased investment will allow us to demonstrate faster to the market why we see generative AI as a benefit. To be clear, much of this is our own intellectual property we have developed that is now deployed in hundreds of our clients.”
“Despite our focus on investing in technology, due to our size, scale, and the regular implementation of our technology-infused solutions, historically, our costs of developing, maintaining, and integrating new technologies were not material on a stand-alone basis. In fiscal year 2024, we increased our investment in technology to approximately 1% of revenue, including expenses related to the development of our new iX suite of technology, as well as pilot programs for clients related to the use of GenAI.”
“Flow-through from revenue growth and efficiency gains across our business more than offset investments to ramp new programs and accelerated investment in AI development and deployment.”
“We have an extensive R&T department that is innovating internally for our own workforce, as well as for customers around all forms of automation, including Generative AI.”
What else could explain it
- line composition: The spend sits across cost of revenue and SG&A with no line of its own; the model and compute bill behind iX Hello is never mentioned.
- other: The direction is for iX Suite expenditures; the CEO also says the company is expanding specialized AI talent (claim c9), which may sit in this channel or in services delivery.
Quotes
“At the same time, we are continuing to invest in our future by upskilling our people and expanding specialized AI talent to grow new capabilities. Looking ahead to Q4, we are pushing accelerated deployments of AI, but we remain confident in the growth opportunity of our new business revenues and the overall market opportunities.”
“In terms of how we're thinking about spending money on our iX Suite, as we've talked about, we're benefiting from some of the ability to lower our cost base with AI internally on our development. We brought down our expenditures on our iX Suite.”
“We expect that margin profile to continue to build up, and at some point, at critical mass, we expect iX Hero to have effectively SaaS-type margins, but that is a fair bit away.”
By quarter
- Q1 2026described · our inference · offensive · $5.3mn to $18mn
- Q2 2026described · our inference · offensive · $6.8mn to $23mn
- Q3 2026direction only · our inference · offensive · $7.9mn to $22mn